| Biotech Co.* (Country; Symbol) | Pharma Co. (Country) | Type/Product Area | Terms/Details (Date) |
| Abeome Corp.* | Millipore Corp. | Exclusive worldwide marketing and distribution agreement for rights to Abeome's stem cell monoclonal antibody Human Embryonic Stem Cell Antigen-1 | Abeome received an undisclosed up-front payment and also will receive royalties on sales by Millipore (12/4) |
| Acambis plc (UK; LSE:ACM) | Sanofi Pasteur (vaccines arm of Sanofi-Aventis SA; France) | Agreement for another ChimeriVax vaccine, a Phase II West Nile virus vaccine | The deal is worth $80M in up-front and milestone payments tied to development and commercialization of the product in the U.S., plus a "high teens" royalty rate on sales; Acambis will receive $10M up front (11/13) |
| Addex Pharmaceuticals SA (Switzerland; SWX:ADXN) | Merck & Co. Inc. | Drug discovery and development alliance in Parkinson's disease and potentially other central nervous system indications | The deal could be worth up to $110M in up-front and milestone payments for the successful development of one drug; it also entails up to $61M in additional mile-stones for the successful development of additional compounds, as well as royalties; Addex has retained an option to co-promote (12/3) |
| Adolor Corp. (ADLR) | Pfizer Inc. | Agreement for the delta opioid agonists ADL5859 and ADL5747 | The deal includes a $31.9M up-front payment, which includes a $1.9M reimbursement of Phase IIa expenses, and a potential $232.5M in milestone payments; Adolor will take the compounds through Phase IIa, and Pfizer will handle subsequent work; Adolor retains an option to co-promote in the U.S., and the companies will split development costs and revenues 60/40, with Pfizer taking the larger percentage; outside of the U.S., Adolor will receive royalties (12/5) |
| Ambrx Inc.* | Eli Lilly and Co. | Agreement to discover and develop drugs in several therapeutic areas, including metabolic diseases, central nervous system disorders and other diseases | Financial terms were not disclosed, but Ambrx expects to receive an up-front payment and ongoing research support payments; it also might receive milestones if assets resulting from the collaboration are successfully commercialized (12/17) |
| Ambrx Inc.* | Merck & Co. Inc. | Agreement to develop an improved version of the protein Fibroblast Growth Factor 21 for use in metabolic diseases | Ambrx will receive an up-front payment, research fees and potential milestones and royalties, as well as the right to exercise an "end of Phase II" profit-sharing option (12/18) |
| Amicus Therapeutics Inc. (FOLD) | Shire Human Genetic Therapeutics Inc. | Agreement for the ex-U.S. development and commercialization of Amicus's three lead pharmacological chaperone compounds for lysosomal storage disorders: Amigal, Plicera and AT2220 | Amicus stands to get $50M up front as well as up to $150M in clinical and regulatory milestones and $240M in sales milestones; Shire gets rights to the Fabry's disease drug Amigal, the Gaucher's disease drug Plicera and the Pompe disease drug AT2220; Amicus will get tiered, double-digit royalties on all ex-U.S. sales (11/8) |
| AnGes MG Inc. (Japan; PK:AMGXF) | Meyer Pharmaceuticals LLC | Licensing agreement for a drug technology for treating inflammatory conditions such as arthritis and skin disease | The drug is an oligonucleotide designed specifically to block NF-kB, a transcription factor that activates pro-inflammatory genes; it is in Phase II for atopic dermatitis (11/19) |
| Arena Pharmaceuticals Inc. (ARNA) | Siegfried Holdings AG (Switzerland) | Strategic cooperation agreement related to the manu-facturing of lorcaserin hydrochloride | The drug is in Phase III testing in obesity (12/18) |
| Argos Therapeutics Inc.* | Therakos Inc.(unit of Johnson & Johnson) | Agreement granting Therakos exclusive research and development rights based on its regulatory T-cell technology | Terms were not disclosed (11/16) |
| AVEO Pharmaceuticals Inc.* | Eli Lilly and Co. | Collaboration under which both will use AVEO's Human Response Platform as part of a pilot project to identify patient populations likely to be responsive to an investigational cancer compound by Lilly | Financial terms were not disclosed (12/4) |
| BioMS Medical Corp. (Canada; TSX:MS) | Eli Lilly and Co. | Licensing agreement for the Phase III multiple sclerosis drug MBP8298 | The deal is potentially worth more than $497M; BioMS will get $87M up front and as much as $410M in development and sales milestone payments; BioMS will fund three ongoing trials, while Lilly will fund all future trials, manufacturing and marketing (12/18) |
| Biovail Laboratories International SRL (unit of Biovail Corp.; Canada; NYSE: BVF) | Pharma Pass II LLC | Agreement for Biovail to acquire two early-stage product candidates | The deal gives Biovail worldwide rights to BVF-068 for central nervous system disorders and BVF-247 for cardiovascular indications; Pharma Pass gets an undisclosed up-front fee, milestone payments and tiered, single-digit royalties (11/7) |
| Cenomed BioSciences LLC (subsidiary of Abraxis BioScience Inc.; ABII) | ThioPharma Inc. (the Netherlands) | Exclusive drug discovery agreement for the development of technology to deliver Cenomed's psychiatric and neurological drugs across the blood-brain barrier | ThioPharma will receive undisclosed up-front and milestone payments (12/3) |
| ChemDiv Inc.* | Orion Pharma (Finland) | Discovery partnership to deploy the Discovery out-Source platform to create small-molecule therapeutics for Orion's targets | ChemDiv will screen designed chemical libraries against Orion's targets, and Orion will select hit series for subsequent lead optimization (11/30) |
| Compendia Bioscience Inc.* | AstraZeneca plc (UK) | Licensing agreement for Oncomine, a compendium of oncology gene expression profiles and analysis tools | AstraZeneca will conduct a year-long pilot project to evaluate the long-term role of the product in its cancer research programs (12/4) |
| Crucell NV (CRXL; the Netherlands) and DSM Pharmaceutical Products* | Daiichi Sankyo (Japan) | Agreement granting licensing rights for their PER.C6 cell line to Daiichi | Financial terms were not disclosed (11/16) |
| Direvo Biotech AG* (Germany) | Pfizer Inc. | Agreement to develop therapeutic proteases for various disease targets | Direvo will apply its protein-engineering capabilities to create proteases with engineered specificity for those targets and will optimize preclinical candidates; Pfizer will be responsible for development and marketing, and will pay Direvo milestones and royalties on any product sales (11/12) |
| Galapagos NV (Belgium; BR:GLPG) | Eli Lilly and Co. | Partnership to develop new osteoporosis therapies in a deal worth at least $395M | Galapagos will provide Lilly access to 12 of its osteoporosis targets and drug discovery programs; Galapagos will receive an up-front payment of $4.3M, and it is eligible for up to $126.4M in discovery, development and regulatory milestones, as well as double-digit royalties (12/19) |
| Graffinity Pharmaceuticals GmbH* (Germany) | Pfizer Inc. | Collaboration focused on Graffinity's fragment-based drug discovery technology | Graffinity will receive technology access fees and payments for the generation of small-molecule hits against a number of drug targets (11/29) |
| GTx Inc. (GTXI) | Merck & Co. Inc. | Agreement to develop and commercialize selective androgen receptor modulators that target musculoskeletal conditions | The deal is worth at least $500M and includes Ostarine for cancer cachexia; GTx receives $40M up front plus $15M in research reimbursements, as well as $422M in future milestone payments and royalties (11/6) |
| Idera Pharmaceuticals Inc. (IDRA) | Merck KGaA (Germany) | Agreement for worldwide rights in cancer indications to Idera's TLR9 agonists | Merck is paying up to $421M, including $40M cash up front and as much as $381M in milestone payments; Idera also would receive royalties on sales (12/19) |
| InterMune Inc. (ITMN) | Marnac Inc. and KDL GmbH (Switzerland) | Agreement for InterMune to buy out rights to pirfenidone for $13.5M up front and as much as $53.5M later | The drug is for idiopathic pulmonary fibrosis; the new deal also includes world-wide rights to intellectual property not licensed under the previous deal, including patents related to the TNF-alpha activities of the p38-gamma inhibitor (11/26) |
| Lantibio Inc.* and TRB Chemedica* (Switzerland) | Alcon Inc. | License agreement for U.S. rights to a dry eye syndrome product that consists of a TRB formulation containing sodium hyaluronate | Lantibio will conduct the development program, while Alcon will assume responsibility for subsequent marketing, sales and manufacturing in the U.S. market; terms call for up-front and milestone payments, as well as royalties (11/6) |
| Lead Therapeutics Inc.* | Shanghai ChemPartner Co. Ltd. (subsidiary of Shang-Pharma Co. Ltd.; Hong Kong) | Research collaboration providing Lead access to scientists from Shanghai ChemPartner | Further terms were not disclosed (11/14) |
| LipoNova AG (Germany; FSE:L1N) | An unnamed non-European pharmaceutical company | Memorandum of understanding for development and marketing of Reniale, an autologous vaccine for renal-cell carcinoma | The partner will support a planned Phase III trial with the drug and make milestone and royalty payments in exchange for an exclusive license in an undisclosed non-European country (11/27) |
| Locus Pharmaceuticals Inc.* | Ono Pharmaceutical Co. Ltd. (Japan) | Research agreement to apply computational technologies and capabilities in chemistry, biology and crystallography to design and develop investigational new drug application-direct preclinical candidates based on a molecular target selected by Ono | Financial terms were not disclosed ((11/5) |
| Maxygen Inc. (MAXY) | Sanofi Pasteur (arm of Sanofi-Aventis Group; France) | A preclinical dengue virus vaccine deal | It entails $24.5M in up-front and milestone payments for Maxygen's portfolio of dengue virus antigens; Sanofi Pasteur will use the antigens to create a dengue vaccine and will pay Maxygen royalties on worldwide commercialization (12/4) |
| Medivir AB (Sweden; SSE:MVIRB) | Waters Co. | Agreement for Medivir to use the Synapt HDMS to hasten its drug discovery efforts in the area of protease inhibitiors for diseases such as herpes, hepatitis C, HIV, osteoporosis, osteoarthritis and high blood pressure | Medivir intends to use the system for tasks such as elucidation of metabolites and impurities, ligand screening during early drug discovery, protein and peptide work, protein identification and for studying post-translation modifications and target characterization (11/9) |
| Millipore Corp. (NYSE:MIL) | Novozymes AS (Denmark) | Agreement to develop, market and sell animal-free cell culture supplements that help mammalian cells produce the proteins that form the basis of biologic drugs | Further terms were not disclosed (12/11) |
| MorphoSys Inc. (Germany; BE:MOR) | Novartis AG (Switzerland) | Partnership for a 10-year discovery and development alliance for antibodies | Novartis has committed $600M in annual technology access fees and research funding; MorphoSys also will be entitled to milestones and single-digit royalties; it can opt to co-develop the programs (12/3) |
| NexMed Inc. (NEXM) | Warner Chilcott Co. Inc. (subsidiary of Warner Chilcott Ltd.) | Agreement for exclusive U.S. rights to its topically applied alprostadil cream for erectile dysfunction | NexMed submitted a new drug application for the product in September; Nex-Med received an up-front payment and is eligible for additional milestone and royalty payments (11/2) |
| Nitec Pharma AG* (Switzerland) | PAZ GmbH (Germany) | Licensing agreement for worldwide rights to the NF-kB and AP1-inhibitor Tarenflurbil in inflammation and pain applications | Financial terms were not disclosed (11/5) |
| Novavax Inc. (NVAX) | GE Healthcare (a unit of General Electric Co.; UK) | Collaboration to develop and market a pandemic influenza vaccine manufacturing solution forselected countries | The collaboration combines GE Healthcare's bioprocess solutions and Novavax's virus-like particle and manufacturing platform (12/10) |
| OncoMed Pharmaceuticals Inc.* | GlaxoSmithKline plc (UK) | Agreement to discover, develop and commercialize antibodies targeting cancer stem cells | OncoMed will receive an up-front payment composed of cash and equity as well as potential milestones and double-digit royalties; in exchange for its cash, GSK gets an option to license four monoclonal antibodies targeting multiple cancer stem cell targets (12/10) |
| OncoMethylome Sciences (Belgium; BR:ONCOB) | GlaxoSmithKline Biologicals (unit of GlaxoSmithKline plc; UK) | Collaboration to identify DNA methylation biomarkers for certain GSK cancer immunotherapeutics | The project is being funded by a Wallonia (BioWin) research grant (11/26) |
| PregLem SA* | HRA Pharma (France) | Licensing agreement for a late-stage selective progesterone receptor modulator | Further terms were not disclosed (12/4) |
| Pronova BioPharma ASA (Norway; OSLO:PRON) | FMC Corp. | Worldwide license and development agreement to develop products using a novel capsule technology | FMC will apply its technology to Pronova's products while Pronova is responsible for clinical development and for securing regulatory approval (12/14) |
| Regeneron Pharmaceuticals Inc. (REGN) | Sanofi-Aventis (France) | Collaboration to discover, develop and commercialize human therapeutic antibodies in a $1B cash and stock deal | Sanofi is increasing its ownership of Regeneron from 4% to about 19% by purchasing 12M shares at $26 each, or $312M; Sanofi will make an $85M up-front payment to Regeneron, and will provide research funding of up to $475M over the next five years; Sanofi has the exclusive option to co-develop each drug candidate; the companies would share U.S. profits with Sanofi taking the lead in commercialization; Regeneron has an option to co-promote (11/29) |
| Rigel Pharmaceuticals (RIGL) | Merck Serono SA (Germany) | Agreement under which Merck Serono exercised its option to pick up Japanese rights to Rigel's aurora kinase inhibitors | The original deal, signed in October 2005, called for a $10M cash payment to Rigel, $15M in equity, and up to $135M in milestones, as well as the two-year option for the Japanese rights (11/14) |
| RXi Pharmaceuticals Corp.* | Thermo Fisher Scientific Inc. | Exclusive license for RNA interference sequences to an undisclosed number of target genes, with an initial focus in the areas of Type II diabetes, obesity, neurology and oncology, for the ongoing development of RXi's rxRNA compounds | RXi obtained the right to license additional RNAi sequences; financial terms were not disclosed (12/14) |
| Santaris Pharma A/S* (Denmark) | GlaxoSmithKline plc (UK) | Drug discovery and development alliance for Santaris' Locked Nucleic Acid synthetic oligonucleotide chemistry, specifically for its potential to combat viral pathogens | The alliance could be worth more than $700M in up-front, milestone and equity payments; it also includes a $5M equity investment and high single-digit to double-digit royalties on sales (12/19) |
| Tripos Discovery Research Ltd. (UK; subsidiary of Commonwealth Biotechnologies Inc.; CBTE) | Schering-Plough Corp. | Service agreement to design, synthesize and purify high-quality, drug-like compounds to expand Schering-Plough Research Institute's compound collection | TDR will use its design software Chem-Space to collaborate with SPRI for compound libraries, as well as large-scale, high-throughput synthesis, purification and analysis of those compounds (11/8) |
| Urigen Pharmaceuticals Inc. (OTC BB:URGP) | Mattern Pharmaceuticals AG (Switzerland) | Agreement for the in-licensing of Nasobol, an intranasal gel testosterone product for the treatment of male hypo-gonadism | Urigen has acquired worldwide rights to develop and commercialize the product; Mattern will receive an undisclosed up-front number of Urigen common shares and will receive additional milestone payments, as well as royalties (11/27) |
|
Notes: # The information in the chart does not cover agricultural agreements or those between biotech companies. * Private companies are indicated with an asterisk. ** Denotes the date the item ran in BioWorld International.Unless otherwise noted, stock symbols listed are on the Nasdaq market. OTC BB = Over-the-Counter Bulletin Board. | |||
To read more on related topics, click on one of the words below.